ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2733

Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis

Kazuhiro Otani1, Haruyasu Ito1, Kenichiro Hirai2, Kentaro Noda2, Ken Yoshida2, Isamu Kingetsu2 and Daitaro Kurosaka2, 1Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Abatacept, lymphocytes and rheumatoid arthritis (RA), Telomeres

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Telomere is a
component of chromosome, and protects end of chromosome from various stress. Telomere
shortens during cell division, and telomerase maintains telomere length. It was
reported that telomerase activity of lymphocytes is upregulated when the
lymphocytes are activated.

Abatacept
suppress the activation of T lymphocytes which are involved in pathogenesis of
rheumatoid arthritis. Therefore we investigated effect of abatacept on
telomerase activity of lymphocytes of patients with rheumatoid arthritis.

Methods:

This study
included 16 patients who were diagnosed with rheumatoid arthritis based on ACR
2010 criteria and received treatment of abatacept from August 2012 to August
2013. We collected their clinical data and peripheral blood samples before
starting abatacept, 4, 12, 24, and 52 weeks after the treatment. Then we extracted
peripheral blood mononuclear cells using ficoll. And CD3 positive lymphocytes
and CD19 positive lymphocytes were sorted by magnetic beads. Using these cells,
we measured telomerase activity by Telomeric Repeat Amplification Protocol.

Results:

Mean age of
patients was 59.2. Before using abatacept, patients were received various
treatment including prednisolone, conventional disease-modifying anti-rheumatic
drugs and biologic therapy. DAS28-CRP before treatment of abatacept was 3.43,
and that after the treatment was 1.54.

Telomerase
activity of CD3 positive lymphocytes declined from 0.413 to 0.156 (p<0.05)
at 52 weeks after the treatment, and that of CD19 positive lymphocytes also
declined from 0.755 to 0.187 (p<0.05). Telomerase activity of CD19 positive
lymphocytes was significantly downregulated at 4 weeks after the treatment, although
that of CD3 positive lymphocytes was not significantly downregulated. (figure)

Conclusion:

Treatment of
rheumatoid arthritis including abatacept suppressed the activition of T
lymphocytes and B lymphocytes. Telomerase activity of B lymphocytes was
downregulated before that of T lymphocytes. It is suggested that abatacept
directly suppress the activation of B lymphocytes.


Disclosure: K. Otani, Bristol-Myers Squibb, 2; H. Ito, None; K. Hirai, None; K. Noda, None; K. Yoshida, None; I. Kingetsu, None; D. Kurosaka, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Otani K, Ito H, Hirai K, Noda K, Yoshida K, Kingetsu I, Kurosaka D. Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/effect-of-abatacept-on-telomerase-activity-of-lymphocytes-of-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-abatacept-on-telomerase-activity-of-lymphocytes-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology